AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mg
Phase 3CompletedDevelopment Stage
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Dec 3, 2014 → Nov 20, 2025
About AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mg
AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mg is a phase 3 stage product being developed by AstraZeneca for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02296125. Target conditions include Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02296125 | Phase 3 | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer